Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entera Bio Ltd. - Ordinary Shares (NQ:ENTX)

2.380 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Entera Bio Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
121 Stocks That Hit Their 52-Week Low
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. 
Via Benzinga
Entera Bio: Q2 Earnings Insights
  Entera Bio (NASDAQ:ENTX) reported its Q2 earnings results on Thursday, August 11, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO
 
Via Benzinga
Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket
Gainers M-tron Industries, Inc. (NASDAQ: MPTI) rose 57.9% to $24.00 in pre-market trading after surging 10% on Friday. M-tron Industries completed its earlier announced separation from The LGL Group,... 
Via Benzinga
$5.1 Million Bet On Tabula Rasa HealthCare? 3 Penny Stocks Insiders Are Buying
US crude oil futures traded higher by around 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
Recap: Entera Bio Q1 Earnings
Entera Bio (NASDAQ:ENTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Entera Bio Q4 Earnings
Entera Bio (NASDAQ:ENTX) reported its Q4 earnings results on Tuesday, March 8, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022
Upgrades 
Via Benzinga
41 Stocks Moving In Tuesday's Mid-Day Session
Gainers Revlon, Inc. (NYSE: REV) rose 125.5% to $2.6499. Revlon’s stock dropped sharply on Monday after the company is reportedly expected to file for bankruptcy. 
Via Benzinga
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
 Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period... 
Via Benzinga
Follow the Insiders and Buy the Dip in These 3 Stocks
These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments. 
Via InvestorPlace
82 Biggest Movers From Yesterday
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday. 
Via Benzinga
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. 
Via InvestorPlace
4 Penny Stocks Insiders Are Buying: Crexendo, Performant Financial And More
Silver prices surged above $24 per troy ounce for the first time in more than two months and investors also focused on some notable insider... 
Via Benzinga
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste... 
Via Benzinga
Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data
Entera Bio Ltd (NASDAQ: ENTX) has presented the 6-month bone mineral density (BMD) data from its Phase 2 trial of EB613, an oral formulation of human parathyroid... 
Via Benzinga
Neurodegenerative Disease And Cancer Stocks Among Top Biotech Gainers In 2021
Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF IBB advancing about 8% year-to-date compared to the roughly 14% gain for the S&P... 
Via Talk Markets
Topics Stocks
Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021
Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) advancing about 8% year-to-date ... 
Via Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
45 Biggest Movers From Yesterday
Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline Phase 2 bone mineral density data for EB613. First... 
Via Benzinga
Earnings Scheduled For August 16, 2021
Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter. • Data Storage (NASDAQ:DTST) is expected to... 
Via Benzinga
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Where Might Entera Bio Stock End Up After Rallying Wednesday
Entera Bio Ltd (NASDAQ: ENTX) shares rallied higher Wednesday after the company announced it saw positive results from its final six-month bone mineral density results from... 
Via Benzinga
ENTX Stock: The Huge FDA News Sending Entera Bio Soaring
Today, investors in ENTX stock are seeing gains of approximately 40% as the company announced results from one of its clinical trials. 
Via InvestorPlace
Mid-Afternoon Market Update: Patterson Companies Drops On Earnings Miss; Entera Bio Shares Gain
Toward the end of trading Wednesday, the Dow traded down 0.08% to 33,918.98 while the NASDAQ rose 0.16% to 14,276.41. The S&P also rose, gaining 0.05% to 4,248.47. The U.S.... 
Via Benzinga
Topics Stocks
Nasdaq Notches Intraday High, SPX Eyes Third-Straight Win
The Dow Jones Industrial Average is modestly lower this afternoon, walking back this morning's gains to register a 19-point drop. 
Via Talk Markets
Topics Stocks
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday. Entera Bio Climbs... 
Via Benzinga
Why Entera Bio Shares Are Skyrocketing Today
Entera Bio Ltd (NASDAQ: ENTX) shares are trading higher by 47.66% at $6.63 Wednesday after the company announced the topline Phase 2 clinical trial of EB613 met its primary... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises Over 1%; Gemini Therapeutics Shares Slide
Midway through trading Wednesday, the Dow traded up 0.01% to 33,948.64 while the NASDAQ rose 0.19% to 14,280.41. The S&P also rose, gaining 0.10% to 4,250.86. The U.S. has the... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.